Endocrine Pharmacology Practice Questions

Q: Triiodothyronine (T3) as compared to Thyroxine (T4):

Is shorter acting. To understand the differences between **Triiodothyronine (T3)** and **Thyroxine (T4)**, one must look at their binding affinity and metabolic clearance. ### **Explanation of the Correct Answer** **Option B (Is shorter acting) is correct.** T3 has a much lower affinity for plasma proteins (specifically Thyroid Binding Globulin) compared to T4. Because more T3 exists in the "free" active form, it is metabolized and cleared by the body much faster. The half-life of **T3 is approximately 1 day**, whereas the half-life of **T4 is about 7 days**. Consequently, T3 has a shorter duration of action. ### **Why the Other Options are Incorrect** * **A. Is more plasma protein bound:** Incorrect. T4 is 99.9% bound, while T3 is about 99.7% bound. Though the difference seems small, the 10-fold higher concentration of "free" T3 significantly impacts its kinetics. * **C. Is less potent:** Incorrect. T3 is **3 to 5 times more potent** than T4. T3 is the biologically active form that binds to the nuclear thyroid receptor; T4 acts largely as a pro-hormone. * **D. Has delayed action:** Incorrect. Because T3 does not need to be deiodinated (unlike T4) and binds directly to receptors, it has a **rapid onset of action** compared to the lag period seen with T4. ### **NEET-PG High-Yield Pearls** * **Drug of Choice:** Levothyroxine (T4) is the drug of choice for hypothyroidism due to its long half-life (once-daily dosing) and stable blood levels. * **Myxedema Coma:** Liothyronine (T3) is preferred in emergencies due to its rapid onset of action. * **Peripheral Conversion:** T4 is converted to T3 in peripheral tissues by the enzyme **5'-deiodinase**. This conversion is inhibited by **Propylthiouracil (PTU), Propranolol, and Glucocorticoids**—a favorite fact for MCQ examiners. * **Reverse T3 (rT3):** An inactive isomer formed during periods of starvation or severe illness (Euthyroid Sick Syndrome).

Q: Which of the following agents is a dual agonist for both PPAR-α and PPAR-γ receptors?

Beroglitazar. **Explanation:** **Correct Answer: C. Beroglitazar** **Mechanism and Concept:** Beroglitazar belongs to a newer class of drugs known as **Glitazars** (Dual PPAR agonists). These agents act as agonists at both **PPAR-α** (Peroxisome Proliferator-Activated Receptor-alpha) and **PPAR-γ** (gamma) receptors. * **PPAR-α activation:** Leads to a reduction in triglycerides and an increase in HDL (similar to fibrates). * **PPAR-γ activation:** Enhances insulin sensitivity in peripheral tissues (similar to thiazolidinediones). By targeting both receptors, Glitazars aim to treat the "dyslipidemic triad" and insulin resistance simultaneously in patients with Type 2 Diabetes Mellitus. Other examples include Saroglitazar (the first to be approved in India). **Analysis of Incorrect Options:** * **A. Pioglitazone:** This is a pure **PPAR-γ agonist** (Thiazolidinedione). While it has some minor PPAR-α effects compared to Rosiglitazone, it is primarily classified as a PPAR-γ agonist used for insulin sensitization. * **B. Fenofibrate:** This is a fibric acid derivative that acts as a selective **PPAR-α agonist**. Its primary clinical use is the reduction of high triglyceride levels. * **C. Bromocriptine:** This is a **Dopamine (D2) receptor agonist**. A specific quick-release formulation is FDA-approved for Type 2 Diabetes, but its mechanism involves modulating circadian hypothalamic dopamine activity, not PPAR receptors. **High-Yield Clinical Pearls for NEET-PG:** * **Saroglitazar:** The first dual PPAR agonist approved (in India) specifically for diabetic dyslipidemia and Non-Alcoholic Steatohepatitis (NASH). * **PPAR-γ** is associated with side effects like weight gain, edema, and increased risk of bone fractures. * **PPAR-δ (delta):** Some newer experimental agents (Pan-PPAR agonists) target alpha, gamma, and delta receptors.

Q: Lactic acidosis is a common adverse effect of which class of antidiabetic medications?

Phenformin. **Phenformin** belongs to the Biguanide class of antidiabetics. It was withdrawn from the market globally because it significantly increases the risk of **lactic acidosis**. Biguanides inhibit mitochondrial oxidation of lactate and promote anaerobic glycolysis [1]. Phenformin has a high affinity for mitochondrial membranes and a long half-life, leading to a much higher incidence of lactic acidosis (approx. 40–60 cases per 100,000 patient-years) compared to Metformin. **Analysis of Options:** * **A. Metformin:** While also a Biguanide, Metformin has a much lower risk of lactic acidosis (approx. 3 cases per 100,000). It is the first-line drug for Type 2 Diabetes. It only poses a significant risk in patients with severe renal impairment (eGFR <30 ml/min), where the drug accumulates [1]. * **C. Repaglinide:** This is a Meglitinide (K+ ATP channel blocker). Its primary side effect is hypoglycemia and weight gain, not lactic acidosis. * **D. Rosiglitazone:** This is a Thiazolidinedione (PPAR-γ agonist). Its major adverse effects include fluid retention, weight gain, congestive heart failure, and increased risk of bone fractures [1]. **High-Yield Clinical Pearls for NEET-PG:** * **Mechanism of Biguanides:** Activation of AMP-activated protein kinase (AMPK), leading to decreased hepatic gluconeogenesis and increased peripheral glucose uptake [1]. * **Metformin Contraindication:** Should be withheld before and 48 hours after using **IV contrast** to prevent acute kidney injury and subsequent lactic acidosis. * **Drug of Choice:** Metformin remains the drug of choice for obese Type 2 Diabetics as it is "weight neutral" and does not cause hypoglycemia (euglycemic agent).

Q: Chronic treatment with tamoxifen can cause carcinoma of which organ?

Endometrium. **Explanation:** Tamoxifen is a **Selective Estrogen Receptor Modulator (SERM)**. Its mechanism of action is tissue-specific, acting as an estrogen **antagonist** in the breast but as an estrogen **agonist** in the uterus and bone. **Why Endometrium is correct:** In the postmenopausal uterus, tamoxifen exerts a pro-estrogenic effect on the endometrial lining. This leads to endometrial hyperplasia, polyp formation, and significantly increases the risk of **Endometrial Carcinoma** (specifically endometrioid adenocarcinoma). Patients on long-term tamoxifen therapy must be monitored for any abnormal vaginal bleeding. **Why other options are incorrect:** * **Ovary:** Tamoxifen does not have a significant agonistic effect on the ovarian epithelium. In fact, in premenopausal women, it may cause functional ovarian cysts, but it is not a recognized risk factor for ovarian carcinoma. * **Cervix & Vulva:** The estrogenic stimulatory effect of tamoxifen is specific to the endometrial lining. There is no clinical evidence linking tamoxifen use to an increased incidence of cervical or vulvar malignancies. **High-Yield Clinical Pearls for NEET-PG:** * **Dual Action:** Tamoxifen is the drug of choice for ER-positive breast cancer in both pre- and postmenopausal women. * **Bone Benefit:** Due to its agonistic effect on bone, it helps prevent postmenopausal osteoporosis. * **Lipid Profile:** It decreases LDL levels (beneficial). * **Adverse Effects:** Increased risk of **Thromboembolism** (DVT/PE) and **Cataracts**. * **Alternative:** In postmenopausal women, **Aromatase Inhibitors** (e.g., Anastrozole) are often preferred as they do not increase the risk of endometrial cancer.

Q: Pulse steroid therapy can be given in which of the following conditions?

All the above. **Explanation:** **Pulse Steroid Therapy** refers to the administration of supra-pharmacological doses of glucocorticoids (typically **Methylprednisolone 500–1000 mg IV**) over a short period (usually 3–5 days). This technique aims to achieve a rapid, potent anti-inflammatory and immunosuppressive effect while minimizing the long-term side effects associated with chronic steroid use. **Why "All the Above" is Correct:** Pulse therapy is indicated in life-threatening or organ-threatening autoimmune and inflammatory conditions where immediate suppression of the immune system is required: * **Pemphigus Vulgaris:** High-dose steroids are the mainstay to control extensive blistering and prevent fatal fluid loss or secondary infections. * **Acute Renal Allograft Rejection:** It is the first-line treatment to reverse cellular rejection and salvage the transplanted organ. * **Optic Neuritis:** Specifically in Multiple Sclerosis-related cases, IV Methylprednisolone pulses accelerate the recovery of visual function (as per the ONTT trial). **Incorrect Options:** Since all three conditions are classic indications for pulse therapy, selecting any single option would be incomplete. **High-Yield Clinical Pearls for NEET-PG:** * **Drug of Choice:** **Methylprednisolone** is preferred over Dexamethasone due to its better tissue penetration and lower mineralocorticoid (salt-retaining) activity. * **Mechanism:** At these high doses, steroids work via **non-genomic mechanisms** (direct effects on cell membranes and mitochondrial function), providing a faster response than the standard genomic pathway. * **Side Effects to Watch:** Sudden cardiac arrhythmias (due to electrolyte shifts), acute psychosis, and hyperglycemia. * **Other Indications:** Systemic Lupus Erythematosus (SLE) with nephritis, Polyarteritis Nodosa (PAN), and Wegener’s Granulomatosis.

Q: Glibenclamide reduces blood glucose in all of the following EXCEPT:

Type 1 diabetics. **Explanation:** The correct answer is **Type 1 diabetics** because of the specific mechanism of action of Sulfonylureas. **Mechanism of Action:** Glibenclamide is a second-generation sulfonylurea. It works by binding to the **SUR1 subunit** of the ATP-sensitive potassium channels ($K_{ATP}$) on the pancreatic **beta-cells**. This leads to channel closure, cell depolarization, calcium influx, and the subsequent release of **endogenous insulin**. 1. **Why Type 1 Diabetics is the correct answer:** Type 1 Diabetes Mellitus is characterized by the autoimmune destruction of pancreatic beta-cells, leading to an **absolute insulin deficiency**. Since Glibenclamide requires functional beta-cells to stimulate insulin release, it is ineffective in Type 1 patients. 2. **Why other options are incorrect:** * **Non-diabetics:** In healthy individuals, beta-cells are functional. Glibenclamide will trigger insulin release, potentially causing profound hypoglycemia. * **Type 2 diabetics:** These patients have relative insulin deficiency and insulin resistance but retain some beta-cell function, making them the primary candidates for this drug. * **Obese diabetics:** Most obese diabetics have Type 2 DM. While metformin is the preferred first-line agent due to weight neutrality, sulfonylureas still effectively reduce blood glucose in these patients. **NEET-PG High-Yield Pearls:** * **Primary Failure:** When sulfonylureas fail to work from the start (often due to misdiagnosed Type 1 DM or LADA). * **Secondary Failure:** When the drug loses efficacy over years due to progressive beta-cell exhaustion. * **Side Effects:** Hypoglycemia (most common) and weight gain. * **Drug Interaction:** Glibenclamide is metabolized by CYP2C9; drugs like sulfonamides can displace it from plasma proteins, increasing hypoglycemia risk.

Q: Which of the following is an SGLT2 inhibitor approved for the treatment of type 2 diabetes mellitus?

Canagliflozin. **Explanation:** **Correct Answer: C. Canagliflozin** Canagliflozin is a Sodium-Glucose Co-transporter 2 (SGLT2) inhibitor [2]. These drugs act on the proximal convoluted tubule (PCT) of the kidney to inhibit glucose reabsorption, leading to therapeutic glucosuria [2]. This mechanism is insulin-independent, making them effective for lowering HbA1c while also providing cardiovascular and renal protection. **Analysis of Incorrect Options:** * **A. Dulaglutide:** This is a **GLP-1 Receptor Agonist** (incretin mimetic) [1]. It is administered subcutaneously and works by stimulating glucose-dependent insulin secretion and slowing gastric emptying [1]. * **B. Pramlintide:** This is a **synthetic Amylin analogue**. It is used as an adjunct to insulin in both Type 1 and Type 2 DM to suppress glucagon secretion and promote satiety. * **C. Nateglinide:** This belongs to the **Meglitinide** class (Glinides). Like sulfonylureas, it acts as an insulin secretagogue by closing ATP-sensitive K+ channels on pancreatic beta cells, but it has a shorter duration of action. **High-Yield Clinical Pearls for NEET-PG:** * **SGLT2 Inhibitors ("-gliflozins"):** Known for "3 Benefits" — Glucose lowering, Weight loss, and Blood pressure reduction. * **Side Effects:** Increased risk of Genitourinary infections (due to glucosuria), Euglycemic Ketoacidosis, and Fourner’s gangrene (rare). * **Cardiorenal Protection:** Empagliflozin and Canagliflozin are specifically noted for reducing the risk of Major Adverse Cardiovascular Events (MACE) and slowing the progression of Chronic Kidney Disease (CKD). * **Dapagliflozin** is now a cornerstone in the management of Heart Failure with reduced Ejection Fraction (HFrEF), even in non-diabetic patients.

Q: What is the mechanism of action of clomiphene citrate used for infertility?

Blocks estrogen receptors in the hypothalamus. ### Explanation **Correct Option: A (Blocks estrogen receptors in the hypothalamus)** Clomiphene Citrate (CC) is a **Selective Estrogen Receptor Modulator (SERM)**. Its primary mechanism of action is acting as a competitive antagonist to estrogen receptors in the hypothalamus and pituitary gland. By blocking these receptors, CC prevents the brain from sensing circulating estrogen levels (perceived hypoestrogenism). This removes the negative feedback inhibition, leading to an increased secretion of **GnRH** from the hypothalamus and a subsequent rise in **FSH and LH** from the anterior pituitary. The elevated FSH levels stimulate the growth of ovarian follicles, leading to ovulation. **Why other options are incorrect:** * **Option B:** CC actually **interrupts** the negative feedback loop. Providing negative feedback would decrease FSH/LH levels, which would inhibit ovulation (the mechanism of combined oral contraceptives). * **Option C:** CC does not have a direct effect on the ovaries; its action is central (hypothalamic-pituitary axis). The ovarian response is a secondary effect of increased FSH. * **Option D:** CC has no significant effect on tubal motility. In fact, its anti-estrogenic effect can sometimes have a negative impact on cervical mucus (making it thick) and the endometrium. **High-Yield NEET-PG Pearls:** * **First-line drug:** Historically the first-line for WHO Group II ovulation induction (e.g., PCOS), though Letrozole (Aromatase Inhibitor) is now preferred in many guidelines. * **Dosage:** Usually started at 50 mg/day for 5 days, beginning on Day 2, 3, 4, or 5 of the menstrual cycle. * **Side Effects:** Multiple pregnancies (mostly twins, ~8-10%), hot flashes, and ovarian hyperstimulation syndrome (OHSS), though OHSS is less common than with gonadotropins. * **Isomer:** Enclomiphene is the active isomer responsible for the ovulation-inducing effect.

Question 1

Triiodothyronine (T3) as compared to Thyroxine (T4):

Accepted Answer

Is shorter acting

Answer

Is more plasma protein bound

Answer

Is less potent

Answer

Has delayed action

Question 2

Which of the following agents is a dual agonist for both PPAR-α and PPAR-γ receptors?

Accepted Answer

Beroglitazar

Answer

Pioglitazone

Answer

Fenofibrate

Answer

Bromocriptine

Question 3

Lactic acidosis is a common adverse effect of which class of antidiabetic medications?

Accepted Answer

Phenformin

Answer

Metformin

Answer

Repaglinide

Answer

Rosiglitazone

Question 4

Chronic treatment with tamoxifen can cause carcinoma of which organ?

Accepted Answer

Endometrium

Answer

Ovary

Answer

Cervix

Answer

Vulva

Question 5

All of the following preparations of insulin are rapid and short-acting EXCEPT:

Accepted Answer

Glargine

Answer

Lispro

Answer

Aspart

Answer

NPH

Question 6

Pulse steroid therapy can be given in which of the following conditions?

Accepted Answer

All the above

Answer

Pemphigus vulgaris

Answer

Acute renal allograft rejection

Answer

Optic neuritis

Question 7

Glibenclamide reduces blood glucose in all of the following EXCEPT:

Accepted Answer

Type 1 diabetics

Answer

Non-diabetics

Answer

Type 2 diabetics

Answer

Obese diabetics

Question 8

Which of the following is an SGLT2 inhibitor approved for the treatment of type 2 diabetes mellitus?

Accepted Answer

Canagliflozin

Answer

Dulaglutide

Answer

Pramlintide

Answer

Nateglinide

Question 9

What is the drug of choice for bisphosphonate-resistant osteoporosis?

Accepted Answer

Teriparatide

Answer

Denosumab

Answer

Anakinra

Answer

Calcitonin

Question 10

What is the mechanism of action of clomiphene citrate used for infertility?

Accepted Answer

Blocks estrogen receptors in the hypothalamus

Answer

Provides negative feedback on the hypothalamic-pituitary-ovarian axis

Answer

Acts directly on ovarian primordial follicles

Answer

Increases tubal motility

Endocrine Pharmacology — MCQs

Endocrine Pharmacology — MCQs

On this page

Practice by Chapter

Want unlimited practice?